Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Cost of Revenue (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Cost of Revenue data on record, last reported at $532000.0 in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 24.54% year-over-year to $532000.0; the TTM value through Dec 2025 reached $2.1 million, down 25.11%, while the annual FY2025 figure was $2.1 million, 25.11% down from the prior year.
  • Cost of Revenue reached $532000.0 in Q4 2025 per ACRS's latest filing, down from $538000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.3 million in Q2 2021 and bottomed at $506000.0 in Q1 2025.
  • Average Cost of Revenue over 5 years is $852100.0, with a median of $828500.0 recorded in 2023.
  • The widest YoY moves for Cost of Revenue: up 0.12% in 2024, down 40.12% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $1.1 million in 2021, then dropped by 23.67% to $877000.0 in 2022, then dropped by 17.33% to $725000.0 in 2023, then dropped by 2.76% to $705000.0 in 2024, then dropped by 24.54% to $532000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $532000.0 in Q4 2025, $538000.0 in Q3 2025, and $515000.0 in Q2 2025.